AI assistant
HAEMONETICS CORP — Director's Dealing 2022
May 18, 2022
31565_dirs_2022-05-18_d76ccbb0-d6e6-4f5f-a7f4-e84ca2787757.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2022-05-16
Reporting Person: DArecca James (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-16 | Common Stock | A | 4774 | — | Acquired | 10676 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-05-16 | Non-qualified Stock Option (Right to Buy) | $57.60 | A | 11163 | Acquired | 2029-05-16 | Common Stock (11163) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported.
F4: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.